ANNX ▲ +0.8% - Annexon, Inc.
$ANNX - Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
24-SEP-2026 08:01 AM ET
Share this post
More filings for $ANNX
ANNX ▲ +3.1% - Annexon, Inc.Sep 2, 2026ANNX - Annexon, Inc. - SEC Filing Update (07-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 7, 2026$ANNX SEC Filing Update (27-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 27, 2026$ANNX SEC Filing Update (08-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 9, 2026$ANNX SEC Filing Update (08-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 8, 2026
View full $ANNX filing history →💬 Comments
Loading comments…
Leave a comment